Main Menu

This technology includes clean, mycoplasma-free, rabies virus stocks for use in vaccine manufacturing. Rabies virus causes a nearly uniformly fatal disease, but can be prevented by timely vaccination. An inactivated rabies vaccine for human use was first prepared in cell culture in 1964, using the Pitman-Moore (PM) strain of fixed rabies virus. Typical rabies vaccine virus stocks stored at the Centers for Disease Control are heavily contaminated by mycoplasma, there this stock provides an alternative supply which is free of mycoplasma.

This technology includes a new concept to develop a bivalent IRV-IPV combination vaccine against rotavirus and polio using a dissolving microneedle patch. Specifically, we describe the formulation for IRV, the fabrication of a microneedle patch for combined IRV-IPV, and the proof of concept for assessing potential interference of immunogenicity and dose sparing in animal studies. Licensed oral rotavirus vaccines, while effective in developed and middle-income countries, are significantly less effective in reducing cases of severe diarrhea among children in developing countries.

This technology includes Escherichia coli isolate with MCR-1 gene which can be used in the development of diagnostic tests. The MCR-1 gene makes bacteria resistant to the antibiotic colistin, which is used as a last-resort drug to treat patients with multi-drug-resistant infections, including carbapenem-resistant Enterobacteriaceae (CRE). This gene exists on a plasmid, a small piece of DNA that is capable of moving from one bacterium to another, spreading antibiotic resistance among bacterial species.